Spermidine is outselling its evidence, and one trial may change that

Spermidine occupies an awkward position. The biology is attractive, the observational data is suggestive, and the confirmatory human trials that would settle the question have mostly not been run yet.

What it is and where it comes from

Spermidine is a polyamine present in every cell and in a lot of ordinary food: wheat germ, aged cheeses, soy products, mushrooms, and fermented foods. Levels in tissue tend to decline with age, which is where the supplementation argument starts.

Its main mechanism is the induction of autophagy, partly through inhibition of the acetyltransferase EP300. Autophagy is how cells break down and recycle damaged components, and it is one of the more consistently supported levers in ageing biology across species.

The observational case, and its limits

Prospective cohort work has linked higher dietary spermidine intake to lower all-cause mortality, and a 2020 neuroimaging analysis associated intake with cortical thickness and hippocampal volume in older adults. Those findings are why the compound has a following.

They are also exactly the kind of finding that fails to replicate in a randomised trial. People who eat a lot of wheat germ and fermented food are different from people who do not, in ways no statistical adjustment fully captures. Nutritional epidemiology has an unhappy history here.

The trial worth waiting for

The POLYCAD trial is a randomised, double-blind, placebo-controlled study at Aarhus University Hospital testing high-dose spermidine in older adults with coronary artery disease. It closed recruitment in August 2025 with completion expected in 2026, and it is measuring cardiac remodelling, physical fitness, muscle tissue, and inflammatory status.

Whatever it finds will be the most substantial human cardiovascular data on spermidine to date. If it is null, that should change how the compound is sold. Whether it will is a separate question.

How this fits with the other longevity compounds

There is a tidy conceptual model in the recent literature in which spermidine's autophagy induction prevents cells from becoming senescent, while a senolytic such as fisetin removes the ones that already have. Two sequential, non-redundant steps.

That model is elegant and it is currently a hypothesis. Direct evidence for combining these compounds is limited to a small number of registered trials. Buying the whole stack on the strength of a conceptual framework is getting ahead of the data by several years.

Common questions

Can I get enough from food?

Wheat germ is the densest common source, and a diet built around it, aged cheese, and fermented foods reaches intakes similar to the higher end of the cohort studies. Whether that produces the same result as a supplement is untested.

Is it safe?

Short-term human trials have not flagged significant safety problems at typical supplemental doses, but the duration of that evidence is measured in months. Talk to a pharmacist if you take prescription medication.

Sources

1. Comparative narrative review of urolithin A, spermidine and NAD+ precursors — https://doi.org/10.4236/jbm.2026.145031
2. POLYCAD trial record — https://clinicaltrials.gov/study/NCT06186102
3. Natural bioactive compounds targeting key hallmarks of aging — https://www.mdpi.com/2072-6643/18/15/2511